A German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.
Paris-based Klineo SAS has raised €2M to speed up access to clinical trials for oncology patients using an AI platform.
`
University Nottingham spin out Locate Bio Ltd has added £9.2m venture financing led by Mercia Ventures and Business Growth Fund to its £16.2m raised before.
Archaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S.
Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).
Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
AmphiStar BVWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).